Hvis der er kliniske tegn på forværring i disse patienters tilstand, skal der tages relevante forbehold inklusiv seponering af lumiracoxib.
If there is clinical evidence of deterioration in the condition of these patients, appropriate measures including discontinuation of lumiracoxib should be taken.